Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 5:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 71 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Aspirin 325 mg daily Clear all
Completed Phase 4 Interventional

Patent Foramen Ovale in Cryptogenic Stroke Study

NCT00697151
View directory record Official record
Conditions
Ischemic Stroke, Patent Foramen Ovale
Interventions
Warfarin, Aspirin
Drug
Lead sponsor
Columbia University
Other
Eligibility
30 Years to 85 Years
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Oct 8, 2026, 5:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ex Vivo Human Thrombosis Chamber Study

NCT00935506
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Clopidogrel, Aspirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 8, 2026, 5:45 PM EDT
Enrolling by invitation Early Phase 1 Interventional Accepts healthy volunteers

Pathways of Eicosanoid Metabolism

NCT04464070
View directory record Official record
Conditions
Metabolism of Prostaglandin D2
Interventions
niacin, aspirin, PGD2
Dietary Supplement · Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 8, 2026, 5:45 PM EDT
Completed Phase 4 Interventional

Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy

NCT01239004
View directory record Official record
Conditions
Dyslipidemia, Hyperlipidemia, Hyperglycemia
Interventions
Placebo, Colesevelam
Drug
Lead sponsor
Radiant Research
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Chicago, Illinois • Kansas City, Kansas • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2012 · Synced Oct 8, 2026, 5:45 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

NCT00687076
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA)
Drug · Behavioral · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
40 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Oct 8, 2026, 5:45 PM EDT
Not listed Phase 2Phase 3 Interventional

Evaluation of the STARFlex® Septal Closure System in Patients With a Stroke or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO)

NCT00201461
View directory record Official record
Conditions
Patent Foramen Ovale, Stroke, Ischemic Attack, Transient
Interventions
STARFlex septal closure system, Best medical therapy
Device · Drug
Lead sponsor
NMT Medical
Industry
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 30, 2008 · Synced Oct 8, 2026, 5:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Aspirin on Mammogram Density in Healthy Postmenopausal Women With a Moderate or High Level of Breast Density

NCT00470561
View directory record Official record
Conditions
Mammographic Breast Density
Interventions
Aspirin, Placebo
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
55 Years to 75 Years · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 15, 2010 · Synced Oct 8, 2026, 5:45 PM EDT
Not listed Not applicable Interventional

Low Dose Chemotherapy With Aspirin in Patients With Breast Cancer After Neoadjuvant Chemotherapy

NCT01612247
View directory record Official record
Conditions
Breast Cancer
Interventions
Cyclophosphamide and Methotrexate and Aspirin
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Lebanon, New Hampshire • Brooklyn, New York • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 8, 2026, 5:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Effects of Aspirin and Acetaminophen on the Stomach in Healthy Volunteers

NCT00594867
View directory record Official record
Conditions
Healthy
Interventions
Acetaminophen - 4 grams per day + Placebo, Aspirin - 325 mg per day + Placebo, Acetaminophen 4 gram per day + Aspirin 325 mg per day
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 8, 2026, 5:45 PM EDT
Completed Not applicable Interventional Results available

SELECT2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke

NCT03876457
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Endovascular Thrombectomy, Medical Management
Device · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
19
States / cities
Los Angeles, California • Jacksonville, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 8, 2026, 5:45 PM EDT
Recruiting Phase 3 Interventional

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

NCT04045665
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
51
States / cities
Little Rock, Arkansas • Los Angeles, California • Stanford, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 8, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

NCT01042704
View directory record Official record
Conditions
Myeloma
Interventions
Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up
Drug · Other
Lead sponsor
Robert Redner, MD
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
22
States / cities
Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 8, 2026, 5:45 PM EDT
Completed Phase 3 Interventional Results available

Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis

NCT00576693
View directory record Official record
Conditions
Ischemic Stroke
Interventions
intracranial angioplasty and stenting, intensive medical management
Device · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
30 Years to 80 Years
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Glendale, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 8, 2026, 5:45 PM EDT
Not listed Phase 4 Interventional

Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)

NCT02660866
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Placebo + background APT + SMT, Vorapaxar 2.08 mg/d + background APT + SMT.
Drug
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
40 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
12
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Oct 8, 2026, 5:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

NCT01568112
View directory record Official record
Conditions
Healthy
Interventions
BG00012 (dimethyl fumarate), BG00012 placebo, ASA, ASA placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
25 Years to 55 Years
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Oct 8, 2026, 5:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT01355705
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Amrubicin, Lenalidomide, Dexamethasone, Aspirin, Pegfilgrastim
Drug
Lead sponsor
Michaela Liedtke
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Oct 8, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

NeuroCognition After Carotid Recanalization

NCT04219774
View directory record Official record
Conditions
Cognition Disorder, Stroke, Occlusion Carotid
Interventions
Endovascular intervention, Aspirin and Clopidogrel (maximal medical Therapy)
Procedure · Drug
Lead sponsor
Duke University
Other
Eligibility
21 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Iowa City, Iowa • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 8, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy

NCT00691704
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide Induction, Sequential Maintenance Therapy
Drug
Lead sponsor
Cristina Gasparetto
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Oct 8, 2026, 5:45 PM EDT
Completed Phase 3 Interventional Results available

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)

NCT01500434
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
21
States / cities
La Jolla, California • Sacramento, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 8, 2026, 5:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Aleglitazar in Combination With Aspirin in Healthy Volunteers

NCT01188304
View directory record Official record
Conditions
Healthy Volunteer
Interventions
aleglitazar, aspirin, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 8, 2026, 5:45 PM EDT
Completed Phase 4 Interventional Results available

Aspirin Dosing in Diabetic Patients

NCT01201785
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Coronary Artery Disease
Interventions
Aspirin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Oct 8, 2026, 5:45 PM EDT
Completed Phase 3 Interventional Results available

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients

NCT01515657
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PL2200 Aspirin Capsules, Immediate-Release Aspirin Tablets, Enteric-coated aspirin caplets
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
21 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 8, 2026, 5:45 PM EDT
Completed Phase 3 Interventional Results available

Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial

NCT00041938
View directory record Official record
Conditions
Heart Disease, Stroke, Ischemic Heart Disease, Myocardial Infarction
Interventions
aspirin, Warfarin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
2,305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
54
States / cities
Tucson, Arizona • Santa Clara, California • West Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Oct 8, 2026, 5:45 PM EDT
Enrolling by invitation Phase 4 Interventional

LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology

NCT03244020
View directory record Official record
Conditions
Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma, Bone Metastases, Venous Thromboembolism, Hematoma, Anticoagulant-induced Bleeding
Interventions
Aspirin 325mg, Enoxaparin 40Mg/0.4mL Prefilled Syringe
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
2,868 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 8, 2026, 5:45 PM EDT